ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1126

The Outcomes of Carpal Tunnel Injections and Carpal Tunnel Surgery
Abstract Number: 2514

The Pattern of Renal Involvement in Relapsing Cryoglobulinemic Vasculitis After Successful Sustained Viral Response by Direct-Acting Antiviral Treatments
Abstract Number: 1118

The Performance of Behcet’s Disease Clinical Diagnostic Criteria in a Low Prevalence Region. A Retrospective Single Center Cohort Study
Abstract Number: 0840

The Platelet Adenosinergic Axis as a Novel Therapeutic Target for Thrombotic APS
Abstract Number: 2263

The Potential Use of Circulating Extracellular Vesicles for Improved Diagnosis and Therapy in Rheumatic Inflammatory/autoimmune Diseases: Proof of Concept Studies
Abstract Number: 0222

The Prediction of Response to Advanced Therapies on a Joint Level in Rheumatoid Arthritis: The Interpretation of Tenderness and Doppler Ultrasound
Abstract Number: 1896

The Prevalence, Incidence, Risk Factors and Time to Diagnosis of Behcet’s Syndrome in England: A Retrospective Nested Case Control Study in Clinical Practice Research Datalink and Hospital Episode Statistics
Abstract Number: 0137

The Problem of Pain in Rheumatology: Sociodemographic and Disease-related Correlates of Agreement Between Structured Data Elements and Clinical Notes in Chronic Pain Documentation Practices in EHR
Abstract Number: 1226

The Problem of Pain in Systemic Lupus Erythematosus: A Comprehensive Analysis of Pain Distribution Using the CHOIR Body Map and PROMIS Measures
Abstract Number: 1448

The Proportion of Inflammatory Back Pain Patients with an Abnormal Sacral MRI in a Community-Based Primary Care Setting
Abstract Number: 2557

The Relation of Colchicine to Knee/hip Replacement Among People with Gout in a Population-based Cohort Study
Abstract Number: 1195

The Relations of Analgesic Antidepressants Use to Knee or Hip Replacement Among Osteoarthritis Patients Compared to Selective Serotonin Reuptake Inhibitors in a Large Prospective Cohort
Abstract Number: 2011

The Relationship Between Anti-drug Antibodies, Infusion Reactions, and Loss of Urate-lowering Response in Patients with Uncontrolled Gout Treated with Pegloticase
Abstract Number: 1262

The Relationship Between Child Opportunity Index and Burden of Pediatric Systemic Lupus Erythematosus
Abstract Number: 2398

The Relationship Between First-Trimester Maternal Serum 25-Hydroxyvitamin D and Maternal/Fetal Outcomes in Patients with Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].